Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recruiting × Sirolimus × Clear all

Phase

Phase 1/2 7 Phase 2 4 Phase 1 4 Phase 2/3 3 Phase NA 1 Phase 3 1

Status

Completed 8 Active not recruiting 4 Withdrawn 1 Unknown 1 Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 1 Epilepsy 1 Drug Resistant Epilepsy 1

Interventions

Cisplatin 84 Carboplatin 81 pembrolizumab 77 Gemcitabine 67 Paclitaxel 65 Docetaxel 61 Capecitabine 47 Oxaliplatin 44 Fluorouracil 44 Specimen Handling 41 Radiotherapy 41 Bevacizumab 40 Magnetic Resonance Spectroscopy 37 Pemetrexed 35 Drug Therapy 34 Dexamethasone 34 Cyclophosphamide 34 Leucovorin 32 Doxorubicin 31 Irinotecan 30 Rituximab 26 Lenalidomide 25 Injections 25 Vincristine 23 Trastuzumab 23 Radiosurgery 21 Radiation 20 Prednisone 20 toripalimab 19 Radiotherapy, Intensity-Modulated 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05534672 2023-08-08

RaRE-TS

Children's Memorial Health Institute, Poland

Phase 3 Recruiting

Drug Resistant Epilepsy, Epilepsy, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡